Public Article
-
verified
Using Tocilizumab in Sars COV-2 Dısease: Case Report
ISSN: 2687 - 5365Publisher: author   
Using Tocilizumab in Sars COV-2 Dısease: Case Report
Indexed in
Medical Sciences
ARTICLE-FACTOR
1.3
Article Basics Score: 3
Article Transparency Score: 3
Article Operation Score: 3
Article Articles Score: 2
Article Accessibility Score: 3
SUBMIT PAPER ASK QUESTION
International Category Code (ICC):
ICC-1702
Publisher: International Journal Of Academic Medicine And Pharmacy Ne..
International Journal Address (IAA):
IAA.ZONE/268771305365
eISSN
:
2687 - 5365
VALID
ISSN Validator
Abstract
Coronavirus 19 (COVID-19) may cause a cytokine release syndrome inducing the severity of the disease. Various immune modulating agents are suggested due to the lack of definitive treatment and vaccine. In this case report, we aimed to share the clinical course of a Covid 19 patient who was given tocilizumab (TCZ) for severe ARDS on the 5th day of hospitalization. Although, the patient was extubated 12 days after TCZ treatment with a rapid recovery, we believe that more cases are needed to determine the efficiency and timing of TCZ treatment.